结缔组织疾病介入性试验的中止与未发表的程度及原因:一项观察性研究
该观察性研究检索了2000年以来在ClinicalTrials.gov注册的所有结缔组织疾病介入性随机对照试验,共纳入175项研究,发现33%被中止,130项至少纳入1例患者的研究中35%未发表;小样本量(<100例参与者)是研究未完成和未发表的唯一相关因素。
要点
- 175项注册的结缔组织疾病随机对照试验中58项(33%)被中止,主要原因均为患者入组不足。
- 至少纳入1例患者的130项研究中46项(35%)未发表;完成研究发表率81% vs 中止研究22%(P<0.001)。
- 小样本量(<100例参与者)是研究未完成和未发表的唯一相关因素。
核心结论
- 每3项注册的结缔组织疾病随机对照试验中就有1项未能完成或发表,代表资源浪费并引发对隐藏临床数据和患者无收益参与的伦理担忧。
研究设计与样本
- 观察性研究,检索2000年以来在ClinicalTrials.gov注册的所有结缔组织疾病介入性随机对照试验,由两名评价者按预设纳入标准筛选,共纳入175项研究。
主要发现
- 175项研究多为III期、安慰剂对照的药物试验,招募系统性红斑狼疮(51%)、系统性硬化症(20%)、干燥综合征(12%)或其他结缔组织疾病患者。
- 58项(33%)被中止,主要因患者入组不足,不同结缔组织疾病间中止率无差异(P>0.5)。
- 130项至少纳入1例患者的研究中46项(35%)未发表,86项(65%)在完成后中位24个月(四分位距15-41)发表于同行评议期刊。
- 完成研究发表率81% vs 中止研究22%(P<0.001),完成研究显著高于中止研究。
- 仅三分之一的未发表病例能获得未发表原因。
关键数值与推荐
- 小样本量(<100例参与者)是研究未完成和未发表的唯一相关因素。
局限性
- 仅三分之一的未发表病例能获得未发表原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the proportion, the reasons, and the factors associated with the discontinuation or nonpublication of randomized controlled trials (RCTs) on connective tissue diseases (CTDs). METHODS: We searched all interventional RCTs on CTDs registered in ClinicalTrials.gov since 2000. Two reviewers selected studies according to prespecified eligibility criteria. Completion status, publication status, and reported reasons for discontinuation or nonpublication were retrieved on ClinicalTrials.gov, through literature search, and by contacting investigators. Multivariable logistic regression was used to identify factors associated with study noncompletion and nonpublication. RESULTS: We included 175 studies, mostly phase III, placebo-controlled trials on pharmacologic treatments recruiting patients with systemic lupus erythematosus (51%), systemic sclerosis (20%), Sjögren's syndrome (12%), or other CTDs. Fifty-eight (33%) had been discontinued, mainly for insufficient patient accrual, with no differences in discontinuation rates across the CTDs (P > 0.5). Forty-six (35%) of 130 studies having included at least 1 patient were unpublished, and 86 (65%) were published in a peer-reviewed journal after a median of 24 months (interquartile range 15-41) from completion, with a significantly higher publication rate in completed versus discontinued studies (81% versus 22%; P < 0.001). We were able to obtain reasons for nonpublication in one-third of cases. Small sample size (<100 participants) was the only factor associated with study noncompletion and nonpublication. CONCLUSION: One of 3 registered RCTs on CTDs fails to be completed or published. This represents a waste of resources and raises ethical concerns regarding hidden clinical data and unfruitful participation by patients.
引用
- Brigante A, Russo B, Mongin D, et al. Extent of and Reasons for Discontinuation and Nonpublication of Interventional Trials on Connective Tissue Diseases: An Observational Study. Arthritis Care Res (Hoboken). 2022. PMID: 34995004. doi:10.1002/acr.24854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。